Peptides for Testosterone: What the HPG Axis Data Shows

Most men searching for peptides for testosterone want the same thing: a way to raise the hormone without switching off the system that makes it. That is a real distinction, and it maps onto a real piece of anatomy. The compounds in this category act on the hypothalamus and the pituitary, several steps upstream of the testes. In healthy male volunteers, a 90-minute kisspeptin-54 infusion raised mean luteinising hormone from 4.2 to 10.8 U/L against saline, and serum testosterone rose with it (Dhillo 2005).

Key takeaways#

• Kisspeptin-54 infusion in healthy men raised mean 90-minute LH from 4.2 U/L on saline to 10.8 U/L, with a parallel rise in FSH and serum testosterone (P < 0.001 for all three).
• Kisspeptin-10 and kisspeptin-54 produced similar gonadotrophin output at matched doses, while GnRH was roughly three-fold more potent than kisspeptin-10 on LH area under the curve.
• hCG at 250 IU every other day held intratesticular testosterone within 7% of baseline in men whose LH had been suppressed by 95%, which is around 10 to 20% of classic fertility-clinic dosing.
• Sermorelin drives growth hormone from the pituitary without significant change in LH or FSH, so it belongs to a different axis than the testosterone question.
• Every testosterone-stimulating peptide named here sits in section S2.2.1 of the WADA Prohibited List, banned at all times for male athletes in drug-tested sport.

Testosterone peptides for men act on the brain, not the testes#

Serum testosterone is the last step in a four-part cascade, not the first. Kisspeptin neurons in the hypothalamus drive gonadotrophin-releasing hormone (GnRH). GnRH drives luteinising hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. LH drives the Leydig cells in the testes to make testosterone. Testosterone then feeds back negatively on the top two layers, which is the mechanism that makes exogenous testosterone suppressive.

That cascade is why the phrase "testosterone peptides for men" is slightly misleading. None of these compounds are testosterone. They are signals that sit above it, and each one enters the chain at a different height. A molecule acting at the hypothalamus preserves every downstream feedback loop. A molecule acting at the Leydig cell bypasses the brain entirely. Those are two different physiological propositions that happen to share a search term.

Kisspeptin is the upstream switch that raises LH and testosterone#

The kisspeptin peptide family is the most directly evidenced entry in this category, and it earned that position in human volunteers rather than in rodents. In the original double-blind crossover study at Hammersmith Hospital, six male volunteers received a 90-minute intravenous kisspeptin-54 infusion at 4 pmol/kg/min or saline in random order. Mean 90-minute LH was 10.8 U/L on kisspeptin against 4.2 U/L on saline, FSH was 3.9 against 3.2 U/L, and mean 180-minute testosterone was 24.9 against 21.7 nmol/L, all at P < 0.001 (Dhillo 2005). No side effects were observed at any dose in the accompanying dose-finding arm. Plasma half-life came out at roughly 28 minutes.

Two features of that result matter more than the absolute numbers. First, the testosterone rise was modest in men who already had normal baseline levels, which is what a physiological signal should do when the axis is not deficient. Second, the axis stayed intact throughout: LH and FSH both moved, meaning the pituitary did the work rather than being bypassed.

Kisspeptin-10 and kisspeptin-54 perform similarly, and both trail GnRH#

Anyone comparing isoforms to find the best peptide to increase testosterone runs into a head-to-head that has already been done. Healthy men received vehicle, kisspeptin-10, kisspeptin-54 or GnRH intravenously for three hours at 0.1, 0.3 and 1.0 nmol/kg/h. At the top dose, mean LH area under the curve was 10.81 h.IU/L for kisspeptin-10, 14.43 for kisspeptin-54 and 34.06 for GnRH (Narayanaswamy 2016). GnRH was roughly three-fold more potent than kisspeptin-10 and two-fold more potent than kisspeptin-54.

That is a useful finding in both directions. The two kisspeptin isoforms are close enough that the choice between kisspeptin-10 and the longer form is not the variable that decides the outcome. And the fact that direct pituitary stimulation is stronger is not automatically an argument for GnRH, because the authors framed kisspeptin as stimulating gonadotrophins in a more physiological manner. Chronic continuous exposure to a GnRH agonist eventually downregulates the axis, which is precisely how those drugs are used in prostate oncology.

Kisspeptin's clinical development is real and ongoing rather than settled. A Phase 2 protocol at Massachusetts General Hospital is administering pulsatile subcutaneous kisspeptin over two weeks in men and women with idiopathic hypogonadotropic hypogonadism, with an estimated completion in 2028 (NCT05896293). In men with hypoactive sexual desire disorder, a 75-minute kisspeptin-54 infusion at 1 nmol/kg/h increased penile tumescence by up to 56% over placebo in a 32-man randomised crossover trial (Mills 2023). No kisspeptin product holds a marketing authorisation in the US or EU as of September 2026, which is a statement about where the development pipeline currently sits, not about the quality of the data behind it.

hCG replaces the LH signal instead of restarting it#

Human chorionic gonadotropin is the entry that most people already know, and it is structurally an LH mimic that binds the same receptor on the Leydig cell. That makes it powerful and also makes it categorically different from kisspeptin. hCG does not ask the brain to signal. It stands in for the signal the brain is no longer sending.

The dose-response work here is unusually clean. Twenty-nine men with normal reproductive physiology received 200 mg testosterone enanthate weekly, which suppressed LH to 5% and FSH to 3% of baseline, alongside placebo or 125, 250 or 500 IU hCG every other day for three weeks. Intratesticular testosterone collapsed by 94% in the placebo arm, from 1234 to 72 nmol/L. In the hCG arms it tracked dose linearly: 25% below baseline at 125 IU, 7% below at 250 IU, and 26% above at 500 IU (Coviello 2005). The authors noted that these doses are 10 to 20% of the 1250 to 2000 IU two or three times weekly used historically in male infertility.

Two implications follow. Where the goal is preserving testicular function during suppression, the effective dose is far lower than folklore assumes. And because hCG acts below the pituitary, it does nothing to restore hypothalamic signalling and can itself suppress it further with sustained use. Klarovel's guide to hCG for men covers the fertility and testicular-volume literature in more depth.

Sermorelin drives growth hormone and leaves the testosterone axis alone#

Sermorelin is the single biggest adjacent search term in this space, and the honest answer is that it belongs to a neighbouring pathway. Sermorelin is a 29-amino-acid GHRH analog. A review of the growth hormone secretagogue class records that sermorelin, given intravenously or subcutaneously, specifically stimulates GH secretion from the pituitary without any significant change in prolactin, luteinising hormone or follicle-stimulating hormone (Ishida 2020). No LH movement means no Leydig-cell stimulation, and therefore no direct testosterone effect.

Its regulatory history is often misread. Geref, the branded sermorelin product, was approved in 1997 for idiopathic growth hormone deficiency in children with growth failure, and EMD Serono voluntarily discontinued it in 2008. The FDA later determined explicitly that the product was not withdrawn for reasons of safety or effectiveness (Federal Register, 2013). Klarovel's engine catalog lists sermorelin as a once-daily bedtime injection cycled 12 weeks on and 4 weeks off at experience tier 1 (src/lib/engine/constants/peptideCatalog.ts). Active or recent cancer is a contraindication to growth-hormone-axis peptides because of IGF-1 effects on cell proliferation. For the mechanism in full, see the sermorelin GHRH analog guide.

Testagen and oral peptides for testosterone have the thinnest data#

The testagen peptide (the tetrapeptide Lys-Glu-Asp-Gly) comes out of the Khavinson bioregulator programme, a body of Russian work on short peptides that regulate gene expression in specific tissues (Khavinson 2021, Molecules). Published testagen-specific work is preclinical and sparse. No controlled human trial has measured serum testosterone, LH or FSH before and after testagen administration. That is a description of the evidence base, not a verdict on the compound, and the distinction matters: an unstudied molecule and a studied-and-failed molecule are different objects.

Oral peptides for testosterone face a separate and more mechanical problem. Kisspeptin-54 has a plasma half-life of roughly 28 minutes by the intravenous route, and peptides of this length are cleaved in the gut before they reach circulation. When investigators wanted a less invasive route, they went to intranasal rather than oral: intranasal kisspeptin-54 at 12.8 nmol/kg raised serum testosterone from 120 minutes onward, with a peak change from baseline of 4.9 nmol/L in 12 healthy men (Mills 2022). Research suggests the delivery problem is solvable. It has not been solved by swallowing the molecule.

Testosterone peptides side effects begin with the axis you are pushing#

Testosterone peptides side effects do not form one list, because the compounds do not share one mechanism. What they share is a feedback loop that responds to how you signal it.

Continuous stimulation is the recurring failure mode. Chronic subcutaneous kisspeptin-54 at 50 nmol/day for 13 days in adult male rats decreased testicular weight, degenerated the seminiferous tubules and dropped circulating inhibin B. A single day of administration raised LH and testosterone; by day two the response was already gone, which the investigators read as downregulation of the axis (Thompson 2006). This is the same paradox that makes chronic GnRH agonists suppressive, and it is the reason pulsatile delivery dominates the current human protocols. Klarovel's engine cycles kisspeptin at 8 weeks on and 4 weeks off for exactly this reason.

Age changes the arithmetic too. In healthy older men (mean age 59) compared with young men (mean age 29), the hypothalamic response to kisspeptin-54 and the pituitary response to GnRH were both preserved or exaggerated, while the testosterone rise was significantly smaller (Abbara 2018). The bottleneck in the older group was testicular, not central. Age-related decline in serum testosterone is associated with reduced testicular sensitivity rather than with a failure of the hypothalamus to signal. An upstream signal cannot fix a downstream limitation, and that is the clearest single argument for measuring LH and FSH alongside testosterone before assuming which layer is the problem.

Three constraints apply regardless of compound. Every testosterone-stimulating peptide discussed here (chorionic gonadotrophin, LH, GnRH and its agonist analogues, and kisspeptin and its agonist analogues) is listed under S2.2.1 of the WADA Prohibited List, prohibited at all times for men in drug-tested sport, and sermorelin appears under S2.2.4. These are hormone-axis medicinal products, which means clinician supervision rather than self-direction. And none of this has been studied in pregnancy or breastfeeding, so growth-hormone-axis and gonadotrophin-axis compounds should not be used by anyone pregnant, trying to conceive or breastfeeding without specialist guidance. Klarovel's disclosures page sets out how the platform handles regulatory framing.

Where a peptides and testosterone stack actually makes sense#

A peptides and testosterone stack is a coherent idea in exactly one circumstance: when the compounds are acting on different layers and doing different jobs. hCG alongside replacement therapy is the established version of that logic, because replacement handles serum levels while hCG maintains intratesticular testosterone that replacement collapses by 94%. Stacking two upstream stimulators is a different proposition, since they compete for the same downstream capacity and share the same downregulation risk. Preliminary evidence indicates that pulsatile rather than continuous delivery is what keeps an upstream signal working, and a stack that ignores that may support nothing at all.

The category is early and moving. Kisspeptin has a Phase 2 trial running to 2028, a randomised trial in men with low sexual desire behind it, and an intranasal route already demonstrated in humans. That is a research programme with momentum, and stating plainly that no product has reached authorisation yet is reporting rather than doubt. What has not changed is the sequencing: measure LH and FSH alongside testosterone, identify the layer that is actually limiting, then decide whether a signal from above has anywhere to land. Anyone weighing peptides for testosterone can start that process with the Klarovel process, which builds the protocol from health data first.